During the past decade, CH Pitie Salpetriere; IM2A conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CH Pitie Salpetriere; IM2A" are "Alzheimer Disease" (2 trials) and "Alzheimer's Disease" (1 trials). Many other conditions were trialed in "CH Pitie Salpetriere; IM2A" in a lesser frequency.

Most popular intervention types in "CH Pitie Salpetriere; IM2A" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Gantenerumab" (2 trials), "Placebo" (2 trials) and "Crenezumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Pitie Salpetriere; IM2A" are 3 trials for "All" genders.

Currently, there are NaN active trials in "CH Pitie Salpetriere; IM2A". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in CH Pitie Salpetriere; IM2A, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in CH Pitie Salpetriere; IM2A, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".